Abstract

FORMULATION AND EVALUATION OF CELECOXIB IMMEDIATE RELEASE TABLETS

Prerana Sahu, Anjali, Harish Sharma and Gyanesh Kumar Sahu*

Abstract

Rheumatoid arthritis is the most common inflammatory arthritis and is a major cause of disability. Early theories on the pathogenesis of rheumatoid arthritis focused on autoantibodies and immune complexes. T-cell-mediated antigen-specific responses, T-cell-independent cytokine networks, and aggressive tumour-like behaviour of rheumatoid synovium have also been implicated. More recently, the contribution of autoantibodies has returned to the forefront. Based on the pathogenic mechanisms, specific therapeutic interventions can be designed to suppress synovial inflammation and joint destruction in rheumatoid arthritis. Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase-2 (COX-2) approved to treat patients with rheumatism and osteoarthritis. The main objective of this work was to prepare the optimized formulation of celecoxib immediate release tablets for the treatment of Rheumatoid arthritis. This work is further aimed to analyse, concentration of drug reaching in the body and to work its effect.

Keywords: Rheumatoid arthritis, Celecoxib, Immediate release tablets.